![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 959-967, March 2003
Department of Arthritis and Inflammation Pharmacology (M.M.H.,
A.J., C.S.T.), and Analytical Sciences Center, Discovery Research
(J.M.H., R.L.O.), Pharmacia Corporation, St. Louis, Missouri; and
Department of Global Toxicology (E.A.G.B., A.L., A.O.), and of Skokie
Discovery Biology (K.S.C.), Pharmacia Corporation, Skokie, Illinois
The cyclooxygenase isoforms, COX-1 and COX-2, are the rate limiting
enzymes in the biosynthesis of prostaglandin E2, a major prostaglandin involved in epidermal homeostasis and repair. Epidermal injury results in transient hyperplasia and induction of COX-2 expression. The role of COX-2 in this hyperplasia is unknown, however.
In this study, we characterized the epidermal expression of COX
isozymes following wounding by abrasion in SKH-1 mice using immunohistochemistry, in situ hybridization, and Western analysis. In
addition, we evaluated pivotal keratinocyte functions necessary for the
reparative hyperplasia, including proliferation by
5-bromo-2'deoxy-uridine labeling and differentiation by the expression
of involucrin, keratin 1, and keratin 6. Although COX-1 expression in
keratinocytes remained unchanged during wound healing, COX-2 expression
was induced coincidentally with keratinocyte proliferation and keratin 6 expression, suggesting a role for COX-2 in epidermal repair. The role
of COX-2 was also evaluated using the selective COX-2 inhibitor
SC-791 and the traditional COX inhibitors indomethacin and
diclofenac. Neither inhibitor altered keratinocyte proliferation or
differentiation following abrasion, in contrast to dexamethasone, which
delayed these responses. Our results indicated that, although COX-2
expression was coincident with transient epidermal hyperplasia and
keratinocyte proliferation/differentiation during the healing of
epidermal injury, it does not play a pivotal role in this repair process.
This article has been cited by other articles:
![]() |
M. K. Wax, D. D. Reh, and M. M. Levack Effect of Celecoxib on Fasciocutaneous Flap Survival and Revascularization Arch Facial Plast Surg, March 1, 2007; 9(2): 120 - 124. [Abstract] [Full Text] [PDF] |
||||